Zoryve 0.15 % (Roflumilast CREAM) 0.15 %

Roflumilast works by inhibiting the enzyme phosphodiesterase-4 (PDE4), which is responsible for breaking down cyclic AMP in cells. By inhibiting PDE4, roflumilast increases the levels of cyclic AMP, leading to a reduction in the production of inflammatory cytokines. This anti-inflammatory effect helps alleviate symptoms of skin conditions like atopic dermatitis.

The usual dose of Zoryve 0.15% is applied to the affected areas of the skin once daily. The cream should be rubbed in completely. The prescriber will determine the appropriate duration of treatment based on the patient's condition and response to the medication.

The safety of Zoryve 0.15% during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider before using this medication if you are pregnant, planning to become pregnant, or breastfeeding. The potential benefits and risks should be carefully considered.

To order Zoryve 0.15% from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will then provide pricing, availability, shipping details, and the necessary import paperwork.

Zoryve 0.15% is a topical PDE4 inhibitor specifically designed to reduce inflammation in the skin. Compared to other treatments like topical corticosteroids, Zoryve 0.15% offers a non-steroidal option that can be used for longer periods without the risk of skin thinning. However, the choice of treatment depends on individual patient needs and should be discussed with a healthcare provider.

Zoryve 0.15% should be stored at room temperature, protected from light and moisture. Keep the cream out of reach of children. Avoid freezing the medication. Always follow the storage instructions provided on the packaging or by your healthcare provider to ensure the medication remains effective.

Zoryve 0.15% is applied topically to the affected areas of the skin once daily. The cream should be gently rubbed in until it is completely absorbed. Wash your hands after applying the cream, unless you are treating your hands. Avoid getting the cream in your eyes, mouth, or vagina, and rinse immediately with plenty of water if contact occurs.

The most serious risks associated with Zoryve 0.15% include severe allergic reactions, such as rash, itching, swelling, severe dizziness, or trouble breathing. Application site urticaria (hives) has also been reported. If you experience any of these symptoms, seek medical attention immediately.

Zoryve 0.15% should not be used by individuals who are allergic to roflumilast or any of its ingredients. It is also not recommended for use in children under 6 years of age, as its safety and effectiveness in this age group have not been established. Patients with moderate to severe liver impairment should use this medication with caution.